Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
Kwon M, Kim G, Kim R, Kim KT, Kim ST, Smith S, Mortimer PGS, Hong JY, Loembé AB, Irurzun-Arana I, Koulai L, Kim KM, Kang WK, Dean E, Park WY, Lee J. Kwon M, et al. Among authors: mortimer pgs. J Immunother Cancer. 2022 Jul;10(7):e005041. doi: 10.1136/jitc-2022-005041. J Immunother Cancer. 2022. PMID: 35790315 Free PMC article. Clinical Trial.
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.
Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS, Odegaard JI, Harrington EA, Lee J, Lee T, Oh SY, Kang JH, Kim JH, Kim Y, Ji JH, Kim YS, Lee KE, Kim J, Sohn TS, An JY, Choi MG, Lee JH, Bae JM, Kim S, Kim JJ, Min YW, Min BH, Kim NKD, Luke S, Kim YH, Hong JY, Park SH, Park JO, Park YS, Lim HY, Talasaz A, Hollingsworth SJ, Kim KM, Kang WK. Lee J, et al. Among authors: mortimer pgs. Cancer Discov. 2019 Oct;9(10):1388-1405. doi: 10.1158/2159-8290.CD-19-0442. Epub 2019 Jul 17. Cancer Discov. 2019. PMID: 31315834
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Kim ST, Smith SA, Mortimer P, Loembé AB, Cho H, Kim KM, Smith C, Willis S, Irurzun-Arana I, Berges A, Hong JY, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kozarewa I, Pierce AJ, Dean E, Lee J. Kim ST, et al. Clin Cancer Res. 2021 Sep 1;27(17):4700-4709. doi: 10.1158/1078-0432.CCR-21-0251. Epub 2021 May 11. Clin Cancer Res. 2021. PMID: 33975862 Free PMC article. Clinical Trial.
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP. Mahdi H, et al. JCO Precis Oncol. 2021 Sep 7;5:PO.20.00439. doi: 10.1200/PO.20.00439. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34527850 Free PMC article. Clinical Trial.
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy.
Kim R, Kwon M, An M, Kim ST, Smith SA, Loembé AB, Mortimer PGS, Armenia J, Lukashchuk N, Shah N, Dean E, Park WY, Lee J. Kim R, et al. Among authors: mortimer pgs. Ann Oncol. 2022 Feb;33(2):193-203. doi: 10.1016/j.annonc.2021.10.009. Epub 2021 Oct 25. Ann Oncol. 2022. PMID: 34710570 Free article. Clinical Trial.
20 results